Stockscreener 앱 받기
0.3399
1.68%
0.0056
시간 외 거래:
.34
0.0001
+0.03%
전일 마감가:
$0.3343
열려 있는:
$0.3229
하루 거래량:
2.53M
Relative Volume:
0.47
시가총액:
$41.66M
수익:
$36.86M
순이익/손실:
$-171.67M
주가수익비율:
-0.2266
EPS:
-1.5
순현금흐름:
$-171.05M
1주 성능:
-17.12%
1개월 성능:
-35.06%
6개월 성능:
-83.34%
1년 성능:
-91.95%
1일 변동 폭
$0.32
$0.3703
1주일 범위
$0.32
$0.42
52주 변동 폭
$0.32
$4.64
Mersana Therapeutics Inc Stock (MRSN) Company Profile
명칭
Mersana Therapeutics Inc
전화
617-498-0020
주소
840 MEMORIAL DRIVE, CAMBRIDGE
MRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.3399 | 41.66M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | William Blair | Outperform |
| 2024-11-15 | 재개 | Citigroup | Buy |
| 2024-03-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-27 | 다운그레이드 | Truist | Buy → Hold |
| 2023-07-27 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-06-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 개시 | Guggenheim | Buy |
| 2023-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 개시 | Citigroup | Buy |
| 2022-11-21 | 개시 | Truist | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-08-30 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-04-29 | 개시 | BTIG Research | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-11-14 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
When Would Be The Best Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - stocksregister.com
Mersana Therapeutics Announces Upcoming Oral Presentation - GlobeNewswire
FDA Fast-Tracked Breast Cancer Drug Shows Promise: Key Clinical Data Coming at ESMO 2025 - Stock Titan
Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World
MRSN stock plunges to 52-week low of $0.37 amid market challenges - Investing.com India
MRSN stock plunges to 52-week low of $0.37 amid market challenges By Investing.com - Investing.com South Africa
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - simplywall.st
MRSN stock touches 52-week low at $0.43 amid sharp decline - Investing.com India
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MRSN stock plunges to 52-week low of $0.45 amid market challenges - Investing.com Australia
Mersana at Leerink Global Healthcare Conference: Strategic ADC Insights By Investing.com - Investing.com Canada
MRSN stock plunges to 52-week low of $0.45 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimates for Mersana Therapeutics Lowered by Wedbush - MarketBeat
Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Simply Wall St
Mersana Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Brokers Issue Forecasts for MRSN Q1 Earnings - Defense World
Q1 EPS Estimate for Mersana Therapeutics Reduced by Analyst - Defense World
Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Yahoo Finance
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - MSN
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call Transcript - Insider Monkey
Mersana Therapeutics (NASDAQ:MRSN) Receives “Outperform” Rating from Wedbush - Defense World
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Mersana Therapeutics’ Viability in Question Amidst Persistent Financial Losses and Funding Challenges - TipRanks
Mersana Therapeutics Reports Progress and Financial Results - TipRanks
Mersana Therapeutics’ Earnings Call Highlights Clinical Progress and Financial Gains - TipRanks
Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast By Investing.com - Investing.com Canada
Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast - Investing.com India
Mersana Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Mersana Therapeutics reports Q4 EPS (11c), consensus (17c) - TipRanks
Mersana Therapeutics, Inc. SEC 10-K Report - TradingView
Mersana Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Mersana Therapeutics Announces Positive Phase 1 Clinical Data - TipRanks
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Mersana's ADC Pipeline Advances: FDA Fast Track Designation as Q4 Losses Narrow - StockTitan
What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings - GuruFocus.com
MRSN stock touches 52-week low at $0.49 amid sharp annual decline - Investing.com Australia
William Blair starts Mersana stock with Outperform rating - MSN
Mersana Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa
Mersana Therapeutics faces Nasdaq delisting over share price - Investing.com
MRSN stock touches 52-week low at $0.49 amid sharp annual decline By Investing.com - Investing.com South Africa
Mersana Therapeutics Inc (MRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):